O'Connor James Joseph 4

What Happened James Joseph O'Connor, Chief Business Officer and General Counsel of Minerva Neurosciences (NERV), received an award of 350,800 derivative securities on April 21, 2026, reported on a Form 4 filed April 22, 2026. The Form 4 lists the acquisition price as $0.00 (i.e., an equity award/option grant recorded as a derivative), so there was no cash outlay reported at grant.

Key Details

• Transaction date: 2026-04-21; Form 4 filed: 2026-04-22 (timely filing).
• Transaction type/code: A — Grant / award (derivative securities).
• Amount: 350,800 shares; price shown on Form 4: $0.00.
• Shares owned after transaction: not specified in the provided filing.
• Footnote: Vesting — 25% vests on April 21, 2027, then the remainder vests in equal quarterly installments over the following 3 years.
• No indication in this filing of an immediate sale or cashless exercise.

Context This was a compensation-related equity award (derivative/stock-option-style grant) rather than a market purchase or sale. Such grants are common for executives and vest over time to align incentives; they do not by themselves signal an insider’s intent to buy or sell shares. Review the company's proxy or award agreement for exercise price and full terms if you need details on potential future dilution or monetary value.